Book contents
- Complications and Outcomes of Assisted Reproduction
- Complications and Outcomes of Assisted Reproduction
- Copyright page
- Dedication
- Contents
- Contributors
- 1 Ovarian Cancer Following Use of Clomiphene and Gonadotropin in Assisted Reproduction
- 2 Congenital Anomalies Following Assisted Reproductive Technology
- 3 Extra-uterine Pregnancy After Artificial Reproductive Technology
- 4 Minimizing Multiple Pregnancy After Assisted Reproductive Technology
- 5 Prevention of Multiple Pregnancy after IUI and Ovarian Stimulation
- 6 Obstetric Complications of Twin Pregnancy Following Assisted Reproductive Technology
- 7 Selection of a Single Embryo for Transfer
- 8 Complications of Oocyte Retrieval in Assisted Reproduction
- 9 Ultrasound Monitoring in ART Have We Made Any Progress?
- 10 Complications of Polycystic Ovary Syndrome in Assisted Reproduction Technology
- 11 Classification and Pathophysiology of Ovarian Hyperstimulation Syndrome
- 12 Genetics of Ovarian Hyperstimulation Syndrome
- 13 Prediction and Prevention of Ovarian Hyperstimulation Syndrome
- 14 Treatment of Ovarian Hyperstimulation Syndrome
- 15 Elimination of OHSS by GnRH Agonist and Freezing Embryos
- 16 Ethical and Legal Issues Arising from Complications of ART
- 17 Complications of Gestational Surrogacy
- 18 Complications of Male Fertility Surgery for Sperm Retrieval in the Azoospermic Male
- 19 Impediments, Challenges, and Hurdles for Lesbian, Gay, Bisexual, and Transgender Persons Seeking Reproductive Medicine
- 20 Political Emotions and Reproductive Medicine From Individual Suffering to European Regulation
- Index
- References
10 - Complications of Polycystic Ovary Syndrome in Assisted Reproduction Technology
Published online by Cambridge University Press: 31 March 2017
Book contents
- Complications and Outcomes of Assisted Reproduction
- Complications and Outcomes of Assisted Reproduction
- Copyright page
- Dedication
- Contents
- Contributors
- 1 Ovarian Cancer Following Use of Clomiphene and Gonadotropin in Assisted Reproduction
- 2 Congenital Anomalies Following Assisted Reproductive Technology
- 3 Extra-uterine Pregnancy After Artificial Reproductive Technology
- 4 Minimizing Multiple Pregnancy After Assisted Reproductive Technology
- 5 Prevention of Multiple Pregnancy after IUI and Ovarian Stimulation
- 6 Obstetric Complications of Twin Pregnancy Following Assisted Reproductive Technology
- 7 Selection of a Single Embryo for Transfer
- 8 Complications of Oocyte Retrieval in Assisted Reproduction
- 9 Ultrasound Monitoring in ART Have We Made Any Progress?
- 10 Complications of Polycystic Ovary Syndrome in Assisted Reproduction Technology
- 11 Classification and Pathophysiology of Ovarian Hyperstimulation Syndrome
- 12 Genetics of Ovarian Hyperstimulation Syndrome
- 13 Prediction and Prevention of Ovarian Hyperstimulation Syndrome
- 14 Treatment of Ovarian Hyperstimulation Syndrome
- 15 Elimination of OHSS by GnRH Agonist and Freezing Embryos
- 16 Ethical and Legal Issues Arising from Complications of ART
- 17 Complications of Gestational Surrogacy
- 18 Complications of Male Fertility Surgery for Sperm Retrieval in the Azoospermic Male
- 19 Impediments, Challenges, and Hurdles for Lesbian, Gay, Bisexual, and Transgender Persons Seeking Reproductive Medicine
- 20 Political Emotions and Reproductive Medicine From Individual Suffering to European Regulation
- Index
- References
- Type
- Chapter
- Information
- Complications and Outcomes of Assisted Reproduction , pp. 98 - 107Publisher: Cambridge University PressPrint publication year: 2017
References
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008; 23: 462–477.CrossRefGoogle Scholar
Messinis, I E. Ovulation induction: a mini review. Hum Reprod 2005; 20: 2688–2697.CrossRefGoogle ScholarPubMed
Messinis, I E, Milingos, S D. Current and future status of ovulation induction in polycystic ovary syndrome. Hum Reprod Update 1997; 3: 235–253.CrossRefGoogle ScholarPubMed
Galazis, N, Zertalis, M, Haoula, Z, et al. Is ultrasound monitoring of the ovaries during ovulation induction by clomiphene citrate essential? A systematic review. J Obstet Gynaecol 2011; 31: 566–571.CrossRefGoogle ScholarPubMed
Smith, Y R, Randolph, J F Jr, Christman, G M, et al. Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction. Fertil Steril 1998; 70: 165–168.CrossRefGoogle ScholarPubMed
Coughlan, C, Fitzgerald, J, Milne, P, et al. Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities? J Obstet Gynaecol 2010; 30: 393–396.CrossRefGoogle ScholarPubMed
Adashi, E Y. Ovulation induction: clomiphene citrate. In: Adashi, E Y, Rock, J A, Rosenwaks, Z, eds. Reproductive Endocrinology, Surgery and Technology. Lippincott-Raven, Philadelphia. 1996; 1181–1206.Google Scholar
Messinis, I E, Nillius, S J. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet Gynecol Scand 1982; 61: 377–379.Google ScholarPubMed
de Paula Guedes Neto, E, Savaris, R F, von Eye Corleta, H, et al. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril 2011; 96: 769–773.CrossRefGoogle ScholarPubMed
The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998; 83: 1507–1514.Google Scholar
Messinis, I E, Bergh, T, Wide, L. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril 1988; 50: 31–35.CrossRefGoogle ScholarPubMed
Franks, S, Adams, J, Mason, H, et al. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 1985; 12: 605–632.CrossRefGoogle ScholarPubMed
Christin-Maitre, S, Hugues, JN, Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003; 18: 1626–1631.CrossRefGoogle ScholarPubMed
Shoham, Z, Di Carlo, C, Patel, A, et al. Is it possible to run a successful ovulation induction program based solely on ultrasound monitoring? The importance of endometrial measurements. Fertil Steril 1991; 56: 836–841.CrossRefGoogle Scholar
Baird, D T. Is there a place for different isoforms of FSH in clinical medicine? IV. The clinician’s point of view. Hum Reprod 2001; 16: 1316–1318.CrossRefGoogle Scholar
Loumaye, E, Engrand, P, Shoham, Z, et al. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314–322.CrossRefGoogle Scholar
Casper, R F, Mitwally, M F. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol 2011; 54: 685–695.CrossRefGoogle ScholarPubMed
Franik, S, Kremer, J A, Nelen, W L, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; 2: CD010287.Google Scholar
Farquhar, C, Brown, J, Marjoribanks, J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2012; 6: CD001122.Google Scholar
Amer, S A, Li, T C, Metwally, M, et al. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod 2009; 24: 219–225.CrossRefGoogle ScholarPubMed
Mercorio, F, Mercorio, A, Di Spiezio Sardo, A, et al. Evaluation of ovarian adhesion formation after laparoscopic ovarian drilling by second-look minilaparoscopy. Fertil Steril 2008; 89: 1229–1233.CrossRefGoogle ScholarPubMed
Api, M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol 2009; 25: 159–165.CrossRefGoogle ScholarPubMed
Legro, R S, Barnhart, H X, Schlaff, W D, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551–566.CrossRefGoogle ScholarPubMed
Moll, E, Bossuyt, P M, Korevaar, J C, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. Br Med J 2006; 332: 1485.CrossRefGoogle ScholarPubMed
Moll, E, van der Veen, F, van Wely, M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007; 13: 527–537.CrossRefGoogle ScholarPubMed
Swanton, A, Storey, L, McVeigh, E, et al. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol 2010; 149: 68–71.CrossRefGoogle ScholarPubMed
Kodama, H, Fukuda, J, Karube, H, et al. High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Hum Reprod 1995; 10: 1962–1967.CrossRefGoogle ScholarPubMed
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47.CrossRefGoogle Scholar
Aflatoonian, A, Oskouian, H, Ahmadi, S, et al. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm). J Assist Reprod Genet 2009; 26: 319–325.CrossRefGoogle ScholarPubMed
Jayaprakasan, K, Chan, Y, Islam, R, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 2012; 98: 657–663.CrossRefGoogle Scholar
Vendola, K A, Zhou, J, Wang, J, et al. Androgens stimulate primordial follicle development in the primate ovary. Biol Reprod 1999; 61: 353–357.CrossRefGoogle Scholar
Dale, P O, Tanbo, T, Haug, E, et al. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod 1998; 13: 567–570.CrossRefGoogle ScholarPubMed
Neulen, J, Yan, Z, Raczek, S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80: 1967–1971.Google ScholarPubMed
Gómez, R, Ferrero, H, Delgado-Rosas, F, et al. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab 2011; 96: 2484–2492.CrossRefGoogle Scholar
Al-Inany, H G, Youssef, M A, Aboulghar, M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011; CD001750.Google ScholarPubMed
Lin, H, Li, Y, Li, L, et al. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS ONE 2014; 9: e91796.CrossRefGoogle ScholarPubMed
Vrtacnik-Bokal, E, Virant Klun, I, Verdenik, I. Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS. Reprod Biomed Online 2009; 18: 21–28.CrossRefGoogle ScholarPubMed
Itskovitz, J, Boldes, R, Levron, J, et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213–220.CrossRefGoogle ScholarPubMed
Cerrillo, M, Pacheco, A, Rodríguez, S, et al. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertil Steril 2011; 95: 2517–2519.CrossRefGoogle ScholarPubMed
Castillo, J C, Dolz, M, Bienvenido, E, et al. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 2010; 20: 175–181.CrossRefGoogle ScholarPubMed
Engmann, L, DiLuigi, A, Schmidt, D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84–91.CrossRefGoogle ScholarPubMed
Shapiro, B S, Daneshmand, S T, Garner, F C, et al. Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011; 95: 2715–2717.CrossRefGoogle ScholarPubMed
Humaidan, P, Ejdrup Bredkjaer, H, Westergaard, L G, et al. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93: 847–854.CrossRefGoogle ScholarPubMed
Radesic, B, Tremellen, K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011; 26: 3437–3442.CrossRefGoogle ScholarPubMed
Iliodromiti, S, Blockeel, C, Tremellen, K P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 2013; 28: 2529–2536.CrossRefGoogle ScholarPubMed
Haas, J, Kedem, A, Machtinger, R, et al. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels – a proof of concept. J Ovarian Res 2014; 7: 35.CrossRefGoogle ScholarPubMed
Roque, M, Lattes, K, Serra, S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril 2013; 99: 156–162.CrossRefGoogle ScholarPubMed
Seyhan, A, Ata, B, Polat, M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013; 28: 2522–2528.CrossRefGoogle ScholarPubMed
Humaidan, P, Thomsen, L H, Alsbjerg, B. GnRH a trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients. Hum Reprod 2013; 28: 2593–2594.CrossRefGoogle ScholarPubMed
Fatemi, H M, Popovic-Todorovic, B, Humaidan, P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 2014; 101: 1008–1011.CrossRefGoogle ScholarPubMed
Heijnen, E M, Eijkemans, M J, De Klerk, C, et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007; 369: 743–749.CrossRefGoogle ScholarPubMed
Palomba, S, Falbo, A, Carrillo, L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011; 96: 1384–1390.CrossRefGoogle ScholarPubMed
Palomba, S, Falbo, A, La Sala, G B. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. Br J Obstet Gynaecol 2013; 120: 267–276.CrossRefGoogle ScholarPubMed
Leitao, V M, Moroni, R M, Seko, L M, et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014; 101: 664–675.CrossRefGoogle ScholarPubMed
Gurgan, T, Demirol, A, Guven, S, et al. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril 2011; 96: 53–57.CrossRefGoogle ScholarPubMed